Mazindol

Mazindol

Clinical data
Routes of administration	Oral
ATC code	A08AA05 (WHO)
Legal status
Legal status	US: Schedule IV Schedule IV (International)
Pharmacokinetic data
Bioavailability	93%
Metabolism	Hepatic
Elimination half-life	10-13 hours
Excretion	Renal
Identifiers
CAS Number	22232-71-9
PubChem CID	4020
DrugBank	APRD01085
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C16H13ClN2O
Molar mass	284.74 g/mol

WikiDoc Resources for Mazindol
Articles
Most recent articles on Mazindol Most cited articles on Mazindol Review articles on Mazindol Articles on Mazindol in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Mazindol Images of Mazindol Photos of Mazindol Podcasts & MP3s on Mazindol Videos on Mazindol
Evidence Based Medicine
Cochrane Collaboration on Mazindol Bandolier on Mazindol TRIP on Mazindol
Clinical Trials
Ongoing Trials on Mazindol at Clinical Trials.gov Trial results on Mazindol Clinical Trials on Mazindol at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Mazindol NICE Guidance on Mazindol NHS PRODIGY Guidance FDA on Mazindol CDC on Mazindol
Books
Books on Mazindol
News
Mazindol in the news Be alerted to news on Mazindol News trends on Mazindol
Commentary
Blogs on Mazindol
Definitions
Definitions of Mazindol
Patient Resources / Community
Patient resources on Mazindol Discussion groups on Mazindol Patient Handouts on Mazindol Directions to Hospitals Treating Mazindol Risk calculators and risk factors for Mazindol
Healthcare Provider Resources
Symptoms of Mazindol Causes & Risk Factors for Mazindol Diagnostic studies for Mazindol Treatment of Mazindol
Continuing Medical Education (CME)
CME Programs on Mazindol
International
Mazindol en Espanol Mazindol en Francais
Business
Mazindol in the Marketplace Patents on Mazindol
Experimental / Informatics
List of terms related to Mazindol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Mazindol is a central nervous system stimulant. It is a tricyclic compound (not to be confused with tricyclic antidepressants).

Indications

Mazindol is used in short-term (i.e., a few weeks) treatment of exogenous obesity, in combination with a regimen of weight reduction based on caloric restriction, exercise, and behavior modification in patients with a body mass index of 30 kg of body weight per height in meters squared (kg/m2), or in patients with a body mass index of 27 kg/m2 in the presence of risk factors such as hypertension, diabetes, or hyperlipidemia.

Pharmacology

Mazindol is a sympathomimetic amine, which is similar to amphetamine. It stimulates the central nervous system, which increases heart rate and blood pressure, and decreases appetite. Sympathomimetic anoretics (appetite suppressants) are used in the short-term treatment of obesity. Their appetite-reducing effect tends to decrease after a few weeks of treatment. Because of this, these medicines are useful only during the first few weeks of a weight-loss program.

Mechanism of Action

Although the mechanism of action of the sympathomimetics in the treatment of obesity is not fully known, these medications have pharmacological effects similar to those of amphetamines. Like other sympathomimetic appetite suppressants such as phentermine, mazindol is thought to act as a reuptake inhibitor of norepinephrine.

Frame

Overdose

Symptoms of a mazindol overdose include: restlessness, tremor, rapid breathing, confusion, hallucinations, panic, aggressiveness, nausea, vomiting, diarrhea, an irregular heartbeat, and seizures.

See also

• Norepinephrine reuptake inhibitor